These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Everolimus in renal cell carcinoma. Wang Y Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316 [TBL] [Abstract][Full Text] [Related]
3. Everolimus for the treatment of advanced renal cell carcinoma. Amato R Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment. Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083 [TBL] [Abstract][Full Text] [Related]
5. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Chan HY; Grossman AB; Bukowski RM Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346 [TBL] [Abstract][Full Text] [Related]
6. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Chen JL; Appelbaum DE; Kocherginsky M; Cowey CL; Rathmell WK; McDermott DF; Stadler WM Cancer Med; 2013 Aug; 2(4):545-52. PubMed ID: 24156027 [TBL] [Abstract][Full Text] [Related]
7. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Agarwala SS; Case S Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359 [TBL] [Abstract][Full Text] [Related]
8. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. Huijts CM; Santegoets SJ; van den Eertwegh AJ; Pijpers LS; Haanen JB; de Gruijl TD; Verheul HM; van der Vliet HJ BMC Cancer; 2011 Nov; 11():505. PubMed ID: 22129044 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. Radulovic S; Bjelogrlic SK J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273 [TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Kapoor A; Figlin RA Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of everolimus in renal cell cancer. Amato R; Stepankiw M Expert Opin Pharmacother; 2013 Jun; 14(9):1229-40. PubMed ID: 23578333 [TBL] [Abstract][Full Text] [Related]
12. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Harshman LC; Barbeau S; McMillian A; Srinivas S Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238 [TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741 [TBL] [Abstract][Full Text] [Related]